NCT01153581View on ClinicalTrials.gov

Sex Hormones and Orthostatic Tolerance

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

May 31, 2013

Conditions
Orthostatic Intolerance
Interventions
DRUG

Ganirelix acetate

Ganirelix acetate: .25 ml/day by subcutaneous injection

DRUG

17β-Oestradiol

17 beta estradiol: 0.2 mg/day (patches)

DRUG

Progesterone

progesterone, 200 mg day-1 oral

Trial Locations (1)

06519

John B. Pierce Laboratory, New Haven

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Yale University

OTHER

NCT01153581 - Sex Hormones and Orthostatic Tolerance | Biotech Hunter | Biotech Hunter